Today, BrightPath Biotherapeutics Co., Ltd. announced the completion of payment of the total issue price of 2,415,000 yen for the 21st stock acquisition rights allocated to a third party. The allottee is Phillip Capital Securities Japan Co., Ltd., the exercise period is October 6, 2026 to October 6, 2027. The initial exercise price is 57 yen, with daily trading-day adjustments under an adjustment clause, a floor of 29 yen, and potential shares of 34,500,000 shares. The expected amount of proceeds is 1,952,915,000 yen (note).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4594","jir_company_name":"BrightPath Biotherapeutics Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4594-20261005-01.pdf","jir_short_summary":"Today, BrightPath Biotherapeutics Co., Ltd. announced the completion of payment of the total issue price of 2,415,000 yen for the 21st stock acquisition rights allocated to a third party. The allottee is Phillip Capital Securities Japan Co., Ltd., the exercise period is October 6, 2026 to October 6, 2027. The initial exercise price is 57 yen, with daily trading-day adjustments under an adjustment clause, a floor of 29 yen, and potential shares of 34,500,000 shares. The expected amount of proceeds is 1,952,915,000 yen (note).","jir_summary":"### Overview of Issuance of Stock Acquisition Rights\nBrightPath Biotherapeutics Co., Ltd. issued the 21st stock acquisition rights by third-party allotment, with the allottee being Phillip Capital Securities Japan Co., Ltd. The total issue price is 2,415,000 yen, and the potential number of shares is 34,500,000 shares (100 shares per stock acquisition right). The exercise period is October 6, 2026 to October 6, 2027, and the initial exercise price is 57 yen. A key feature is that the exercise price is adjusted based on 97% of the closing price on each trading day, with a floor set at 29 yen.\n\n### Fundraising and Future Impact\nThe amount of proceeds is expected to be 1,952,915,000 yen, which may fluctuate depending on exercise price adjustments and market conditions. With the completion of payment, the fundraising as part of the capital policy has been completed. A purchase agreement has been concluded which requires board approval for transfer of the subscription rights.","jir_financial_highlights":"Total issue price for stock acquisition rights: 2,415,000 yen (Unknown)\nPotential number of shares: 34,500,000 shares (Unknown)\nExpected amount of proceeds: 1,952,915,000 yen (Unknown)\nInitial exercise price: 57 yen (Unknown)","jir_category":"","jir_hashtags":"#BrightPathBiotherapeutics, #StockAcquisitionRights, #CapitalPolicy","jir_key_figures":"Total issue price of stock acquisition rights: 2,415,000 yen\nPotential number of shares: 34,500,000 shares\nExpected amount of proceeds: 1,952,915,000 yen","jir_meta_title":"BrightPath Biotherapeutics Co., Ltd. \u2014 Notice of Completion of Payment for Stock Acquisition Rights Issue Price | October 2026","jir_meta_description":"Announcement of completion of payment for the 21st stock acquisition rights issued by third-party allotment by BrightPath Biotherapeutics Co., Ltd. Summary includes allottee, exercise price, adjustment terms, potential shares, and expected proceeds.","jir_og_title":"BrightPath Biotherapeutics Co., Ltd. \u2014 Notice of Completion of Payment for Stock Acquisition Rights Issue Price","jir_og_description":"Announcement of third-party allotment of stock acquisition rights and completion of payment. Initial exercise price 57 yen, adjustment terms, potential shares 34,500,000 shares, expected proceeds approximately 1,952,915,000 yen.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59787,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-127206","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n